Roth Capital affirms Ligand Pharmaceuticals (Nasdaq: LGND) with a Buy rating and $127 price target following news from partner Sage ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE